{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:28:51Z","timestamp":1789475331890,"version":"build-2803163510"},"reference-count":33,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Sodium\u2010glucose cotransporter 2 inhibitors (SGLT2is) are particularly effective in preventing adverse outcomes of heart failure and chronic kidney disease, which are highly prevalent in the elderly. Here, we aimed to access the safety of SGLT2i in elderly patients with type 2 diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>We performed a meta\u2010analysis of randomized controlled trials (RCTs) reporting safety outcomes of the elderly (\u226565\u2009years) patients with type 2 diabetes, randomized to an SGLT2i or placebo. We recorded the incidence of acute kidney injury, volume depletion, genital tract infections, urinary tract infections, bone fractures, amputations, diabetic ketoacidosis, hypoglycaemia and drug discontinuation, by group of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Of the 130 RCTs screened, only six reported data on elderly patients. In total, 19\u2009986 patients were included. The SGLT2i discontinuation rate was approximately 20%. The risk of acute kidney injury was significantly lower among SGLT2i users compared with placebo [risk ratio (RR) 0.73; 95% CI 0.62\u20100.87]. SGLT2i were associated with a six\u2010fold increased risk of genital tract infections (RR 6.55; 95% CI 2.09\u201020.5). The rate of amputations was increased only among canagliflozin users (RR 1.94, 95% CI 1.25\u20103). The risk of fractures, urinary tract infection, volume depletion, hypoglycaemia and diabetic ketoacidosis was similar between SGLT2i and placebo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SGLT2is were well tolerated in the elderly. However, older patients are underrepresented in most RCTs and a call for action is need to favour clinical trials reporting safety outcomes stratified by age.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15193","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T22:59:39Z","timestamp":1688511579000},"page":"2963-2969","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Safety of sodium\u2010glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta\u2010analysis of randomized controlled trials"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5125-7434","authenticated-orcid":false,"given":"Mauro","family":"Rigato","sequence":"first","affiliation":[{"name":"Department of Medicine University of Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6510-2097","authenticated-orcid":false,"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1177-0516","authenticated-orcid":false,"given":"Angelo","family":"Avogaro","sequence":"additional","affiliation":[{"name":"Department of Medicine University of Padova  Padova Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc12-1801"},{"key":"e_1_2_11_3_1","volume-title":"IDF Diabetes Atlas","author":"International Diabetes Federation","year":"2021"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-S010"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12670"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-02733-w"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1602116"},{"key":"e_1_2_11_8_1","unstructured":"U.S. Department of Health and Human Serv_ices; U.S. Food and Drug Administration; Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research.Guidance for in_dustry. E7 studies in support of special populations: geriatrics \u2013 questions and answers [Internet].2012. Accessed December 20 2022.https:\/\/www.federalregister.gov\/documents\/2012\/02\/21\/2012\u20103955\/international\u2010conference\u2010on\u2010harmonisation\u2010guidance\u2010on\u2010e7\u2010studies\u2010in\u2010support\u2010of\u2010special\u2010populations"},{"key":"e_1_2_11_9_1","volume-title":"Adequacy of guidance on the elderly regarding medicinal products for human use","author":"Committee for Human Medicinal Products","year":"2006"},{"key":"e_1_2_11_10_1","unstructured":"HigginsJPT ThomasJ ChandlerJ et al. eds.Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane.2019. Accessed December 20 2022.https:\/\/training.cochrane.org\/handbook\/current"},{"key":"e_1_2_11_11_1","unstructured":"Sch\u00fcnemannH Bro\u017cekJ GuyattG OxmanA GRADE Working Group.GRADE Handbook. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach.2013."},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-1476"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.kint.2021.09.005"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.05.005"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14091"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.12881"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afz096"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4955-5"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-019-4839-8"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504720"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024816"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1811744"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106396"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2021.09.015"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13820"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30257-7"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2812"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0573-0"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-016-0382-1"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1701990"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:42Z","timestamp":1761864222000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/dom.15193"],"URL":"https:\/\/doi.org\/10.1111\/dom.15193","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15193\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15193\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15193\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15193\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15193\/v1\/review2","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"2023-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}